Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment

Annals of Hematology

Volumn 92, Issue 4, 2013, Pages 459-469

  Kim, Hyeoung Joon ⁱ   Yi, Jun Ho ^a,b   Huh, Jungwon ^c   Kim, Hee Jin ^a   Kim, Sun Hee ^a   Kim, Sung Hyun ^d   Kim, Kyoung Ha ^e   Do, Young Rok ^f   Mun, Yeung Chul ^c   Kim, Hawk ^g   Kim, Min Kyoung ^h   Kim, Taehyung ^j   Kim, Dennis Dong Hwan ^a,j  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

^d Dong A University   (South Korea)

^e Soonchunhyang University   (South Korea)

^f Keimyung University   (South Korea)

^g Ulsan University College of Medicine   (South Korea)

^h Yeungnam University Hospital   (South Korea)

ⁱ Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^j UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Chronic monomyelocytic leukemia; Copy neutral loss of heterozygosity (CN LOH); Copy number alterations; Myelodysplastic syndrome; Single nucleotide polymorphism based karyotyping

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; CHROMOSOME MAP; DRUG RESISTANCE; EVALUATION; GENETICS; HUMAN GENOME; METHODOLOGY; MICROARRAY ANALYSIS; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CHROMOSOME MAPPING; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOME, HUMAN; HUMANS; KARYOTYPING; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TREATMENT OUTCOME;

MLCS; MLOWN;

EID: 84877070679     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1635-7     Document Type: Article

References (34)

1. Greenberg PL, Attar E, Battiwalla M et al (2008) Myelodysplastic syndromes. J Natl Compr Canc Netw 6:902-926
2. Rollison DE, Howlader N, Smith MT et al (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112:45-52
3. Kantarjian H, Oki Y, Garcia-Manero G et al (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57
4. Lyons RM, Cosgriff TM, Modi SS et al (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850-1856
5. Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440
6. Steensma DP, Baer MR, Slack JL et al (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842-3848
7. Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
8. Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983-992
9. Vardiman JW (2006) Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2006:199-204
10. Faderl S, Kantarjian HM (2004) Novel therapies for myelodysplastic syndromes. Cancer 101:226-241
11. Pozdnyakova O, Miron PM, Tang G et al (2008) Cytogenetic abnormalities in a series of 1,029 patients with primary myelodysplastic syndromes: a report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 113:3331-3340
12. Haase D, Germing U, Schanz J et al (2007) New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110:4385-4395
13. Barresi V, Romano A, Musso N et al (2007) Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes. Genes Chromosomes Cancer 49:1014-1023
14. Bullinger L, Kronke J, Schon C et al (2010) Identification of acquired copy number alterations and uniparental disomies in cytogenetically normal acute myeloid leukemia using high-resolution single-nucleotide polymorphism analysis. Leukemia 24:438-449
15. Nomdedeu JF, Perea G, Estivill C et al (2004) Loss of heterozygosity of the polymorphic PIG3 microsatellite with low frequency in de novo acute myeloid leukemias. Leukemia 18:1148-1149
16. Huh J, Jung CW, Kim HJ et al (2012) Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category. Genes Chromosomes Cancer 52:44-55
17. Huh J, Kim HJ, Jung CW et al (2012) A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. Am J Hematol 87:961-968
18. Yi JH, Huh J, Kim HJ et al (2011) Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. J Clin Oncol 29:4702-4708
19. Miller BJ, Wang D, Krahe R, Wright FA (2003) Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 73:748-767
20. Saeki H, Kitao H, Yoshinaga K et al (2011) Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res 17:1731-1740
21. Mohamedali A, Gaken J, Twine NA et al (2007) Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 110:3365-3373
22. Tiu RV, Gondek LP, O'Keefe CL et al (2011) Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 117:4552-4560
23. Langemeijer SM, Kuiper RP, Berends M et al (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842
24. Itzykson R, Kosmider O, Cluzeau T et al (2010) Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML Post MDS. Blood 116:Abstract 439
25. Nikoloski G, Langemeijer SM, Kuiper RP et al (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665-667
26. Kulasekararaj AG, Mohamedali AM, Smith AE et al (2010) Polycomb complex group gene mutations and their prognostic relevance in 5-azacitidine treated myelodysplastic syndrome patients. Blood 116:Abstract 125
27. Xu F, Li X, Wu L et al (2010) Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 90:643-653
28. Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405-1413
29. Swerdlow S, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissue (IARC WHO classification of tumours), 4th ed. WHO, Geneva
30. Shaffer LG, Slovak ML, Campbell LJ (2009) An international system for human cytogenetic nomenclature. Karger, Basel
31. Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425
32. Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP (2008) Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111:1534-1542
33. Makishima H, Rataul M, Gondek LP et al (2010) FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q). Leuk Res 34:447-453
34. Jasek M, Gondek LP, Bejanyan N et al (2010) TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 24:216-219